Page last updated: 2024-12-05
norbormide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
norbormide: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 12399560 |
| SCHEMBL ID | 436736 |
| MeSH ID | M0046805 |
Synonyms (10)
| Synonym |
|---|
| mcn 1025 |
| s 6999 |
| raticate |
| shoxin |
| norbormide |
| 991-42-4 |
| SCHEMBL436736 |
| (10e)-8-[hydroxy(phenyl)pyridin-2-ylmethyl]-10-[phenyl(pyridin-2-yl)methylidene]-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione |
| Q7050437 |
| AKOS040746163 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, one major drawback of NRB as a viable rodenticide relates to an evolutionary aversion developed by the rat leading to sub-lethal dosing due to either its unpleasant 'taste' or rapid onset of effects." | ( Design and synthesis of prodrugs of the rat selective toxicant norbormide. Bova, S; Brimble, MA; Cavalli, M; Hopkins, B; Laita, O; Linthicum, DS; Rennison, D, 2012) | 0.38 |
| " However, one major drawback of NRB as a viable rodenticide relates to an evolutionary aversion developed by the rat leading to sub-lethal dosing due to either its unpleasant 'taste' or rapid onset of effects." | ( Prodrugs of N-dicarboximide derivatives of the rat selective toxicant norbormide. Bova, S; Brimble, MA; Cavalli, M; Conole, D; Hopkins, B; Jay-Smith, M; Knauf, J; Laita, O; Linthicum, DS; Rennison, D, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (23)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.17%) | 6.00% |
| Case Studies | 1 (4.17%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||